Clinical trial
Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously…
NCT00357461 · Bristol-Myers Squibb, Industry · Withdrawn
Key facts
| NCT number | NCT00357461 |
|---|---|
| Title | Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma |
| Official title | A Randomized Phase II Study of Fixed Dose Ipilimumab (MDX-010) 10 mg/kg Given Alone or in Combination With Two gp100 Peptides Emulsified With Montanide ISA-51 VG for Previously Treated HLA-A * 0201 Positive Subjects With Stage IV Melanoma |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | gp100:209-217(210M) peptide vaccine, gp100:280-288(288V) peptide vaccine, incomplete Freund's adjuvant, ipilimumab |
| Enrollment | 0 |
| Start date | May 1, 2006 |
| First posted | Jul 27, 2006 |
| Last update posted | May 15, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: